Summit Global Investments Purchases New Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Summit Global Investments bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 45,425 shares of the biotechnology company's stock, valued at approximately $779,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after purchasing an additional 645 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in shares of ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after buying an additional 700 shares during the period. Mutual of America Capital Management LLC increased its position in shares of ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after acquiring an additional 751 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after acquiring an additional 897 shares during the period. Finally, GAMMA Investing LLC lifted its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 967 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Remove Ads

ADMA Biologics Stock Performance

NASDAQ ADMA traded up $0.58 on Thursday, hitting $20.28. 2,316,129 shares of the stock were exchanged, compared to its average volume of 3,359,250. The company has a market capitalization of $4.79 billion, a PE ratio of 72.43 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business's fifty day moving average is $16.97 and its 200 day moving average is $18.11. ADMA Biologics, Inc. has a 52 week low of $5.90 and a 52 week high of $23.64.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.